Acutus Medical AFIB · USD

Its shares trade under the ticker AFIB. It has been listed since 6 August 2020. In the fiscal year to 31 December 2024, it reported revenue of $20.2m and a net loss of $9.5m. At that date it held total assets of $28.6m and shareholders' equity of −$11.6m.

Acutus Medical, Inc. engages in the development of medical devices and electrophy equipment. The company is headquartered in Carlsbad, California. The company went IPO on 2020-08-06. The firm designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. The Company’s product portfolio includes access sheaths, transseptal crossing tools, diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Its AcQMap System consists of the single-use AcQMap catheter as well as its console, workstation and software algorithms. With 48 ultrasound transducers interspersed between 48 biopotential electrodes, its mapping catheter collects the data required to create a map of the cardiac anatomy and electrical propagation pathways and patterns. The Company’s software algorithms analyze the biopotential data and maps any type of arrhythmia, including atrial fibrillation, as well as all supraventricular tachycardias and ventricular arrhythmias.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Shaden MarzoukIndependent Chairperson of the Board$73,750
• Dr. David BonitaIndependent Director$50,000
• Dr. Andrew ElbardissiIndependent Director$52,000
• Mr. Jason GarlandIndependent Director$60,000
• Ms. Niamh PellegriniIndependent Director$57,000
• Mr. John SheridanIndependent Director$56,500

Overall

16

Environment

5

Social

21

Governance

23

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.